

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Milbemycin Oxime / Lufenuron Formulation

Manufacturer or supplier's details

Company : MSD

Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Skin sensitisation : Category 1

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 2 (Central nervous system)
repeated exposure

Specific target organ toxicity - : Category 1 (Central nervous system, Lungs, Liver, Stomach)
repeated exposure (Oral)




Short-term (acute) aquatic : Category 1
hazard

Long-term (chronic) aquatic : Category 1
hazard

GHS label elements

Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365220-00011 Date of last issue: 14.04.2025
Date of first issue: 21.09.2020

- Hazard pictograms :   
- Signal word : Danger
- Hazard statements : H317 May cause an allergic skin reaction.
H360D May damage the unborn child.
H372 Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.
- Precautionary statements : **Prevention:**
P203 Obtain, read and follow all safety instructions before use.
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P264 Wash hands thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of the workplace.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- Response:**
P302 + P352 IF ON SKIN: Wash with plenty of water.
P318 IF exposed or concerned, get medical advice.
P333 + P317 If skin irritation or rash occurs: Get medical help.
P362 + P364 Take off contaminated clothing and wash it before reuse.
P391 Collect spillage.
- Storage:**
P405 Store locked up.
- Disposal:**
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|-----------------|-------------|-----------------------|
| Lufenuron (ISO) | 103055-07-8 | >= 30 - < 50 |
| Cellulose | 9004-34-6 | >= 10 - < 20 |

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365220-00011 Date of last issue: 14.04.2025
Date of first issue: 21.09.2020

| | | |
|------------------|-------------|------------------|
| Starch | 9005-25-8 | $\geq 5 - < 10$ |
| Milbemycin Oxime | 129496-10-2 | $\geq 1 - < 2.5$ |

4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.
May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure if swallowed.
May cause damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Avoid breathing dust, fume, gas, mist, vapours or spray.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

Version 4.1 Revision Date: 09.05.2025 SDS Number: 6365220-00011 Date of last issue: 14.04.2025
Date of first issue: 21.09.2020

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|---------------------------|-------------|----------------------------------|--|----------|
| Lufenuron (ISO) | 103055-07-8 | TWA | 200 µg/m ³ (OEB 2) | Internal |
| Further information: DSEN | | | | |
| | | Wipe limit | 100 µg/100 cm ² | Internal |
| Cellulose | 9004-34-6 | TWA | 10 mg/m ³ | ACGIH |
| Starch | 9005-25-8 | TWA | 10 mg/m ³ | ACGIH |
| Milbemycin Oxime | 129496-10-2 | TWA | 0.1 mg/m ³ (OEB2) | Internal |

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Contaminated work clothing should not be allowed out of the workplace.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : solid

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

| | | |
|--|---|--|
| Colour | : | brown |
| Odour | : | odourless |
| Odour Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | Not applicable |
| Flammability (solid, gas) | : | No data available |
| Flammability (liquids) | : | Not applicable |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | Not applicable |
| Relative vapour density | : | Not applicable |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | soluble |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | | |
| Viscosity, kinematic | : | Not applicable |
| Explosive properties | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Molecular weight | : | No data available |

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Particle characteristics
Particle size : No data available

10. STABILITY AND REACTIVITY

| | |
|------------------------------------|--|
| Reactivity | : Not classified as a reactivity hazard. |
| Chemical stability | : Stable under normal conditions. |
| Possibility of hazardous reactions | : Can react with strong oxidizing agents. |
| Conditions to avoid | : None known. |
| Incompatible materials | : Oxidizing agents |
| Hazardous decomposition products | : No hazardous decomposition products are known. |

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 10 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Lufenuron (ISO):

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): 2,350 mg/m3
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Milbemycin Oxime:

Acute oral toxicity : LD50 (Rat): 532 - 863 mg/kg

LD50 (Mouse): 722 - 946 mg/kg

Acute inhalation toxicity : LC50 (Rat): 1,200 mg/m³
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Lufenuron (ISO):

| | |
|---------|----------------------|
| Species | : Rabbit |
| Method | : Draize Test |
| Result | : No skin irritation |

Milbemycin Oxime:

| | |
|---------|---------------------------|
| Species | : Rabbit |
| Method | : OECD Test Guideline 404 |
| Result | : No skin irritation |

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Lufenuron (ISO):

| | |
|---------|---------------------|
| Species | : Rabbit |
| Method | : Draize Test |
| Result | : No eye irritation |

Starch:

| | |
|---------|---------------------|
| Species | : Rabbit |
| Result | : No eye irritation |

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemyacin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Milbemyacin Oxime:

| | | |
|---------|---|-------------------|
| Species | : | Rabbit |
| Result | : | No eye irritation |

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

Lufenuron (ISO):

| | | |
|------------|---|--|
| Test Type | : | Maximisation Test |
| Species | : | Guinea pig |
| Assessment | : | May cause sensitisation by skin contact. |
| Result | : | Sensitiser |

Starch:

| | | |
|-----------------|---|-------------------|
| Test Type | : | Maximisation Test |
| Exposure routes | : | Skin contact |
| Species | : | Guinea pig |
| Result | : | negative |

Milbemyacin Oxime:

| | | |
|-----------------|---|--------------|
| Exposure routes | : | Skin contact |
| Species | : | Guinea pig |
| Result | : | negative |

Germ cell mutagenicity

Not classified based on available information.

Components:

Lufenuron (ISO):

| | | |
|-----------------------|---|----------------------|
| Genotoxicity in vitro | : | Test Type: Ames test |
| | | Result: negative |

Test Type: Mouse Lymphoma
Test system: Chinese hamster cells
Result: negative

Test Type: Cytogenetic assay
Test system: Chinese hamster ovary cells
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: rat hepatocytes
Result: negative

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Result: negative

Test Type: Unscheduled DNA synthesis test (UDS) in testicular cells
Species: Rat
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Milbemycin Oxime:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Components:

Lufenuron (ISO):

| | | |
|-------------------|---|-------------|
| Species | : | Rat |
| Application Route | : | Ingestion |
| Exposure time | : | 18 month(s) |
| Result | : | negative |

| | | |
|------------------------------|---|--|
| Carcinogenicity - Assessment | : | Weight of evidence does not support classification as a carcinogen |
|------------------------------|---|--|

Cellulose:

| | | |
|-------------------|---|-----------|
| Species | : | Rat |
| Application Route | : | Ingestion |
| Exposure time | : | 72 weeks |
| Result | : | negative |

Reproductive toxicity

May damage the unborn child.

Components:

Lufenuron (ISO):

| | | |
|----------------------|---|---|
| Effects on fertility | : | Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: NOAEL: 8.3 mg/kg wet weight Early Embryonic Development: NOAEL: 20.9 mg/kg body weight Result: Animal testing did not show any effects on fertility. |
|----------------------|---|---|

| | | |
|-------------------------------|---|---|
| Effects on foetal development | : | Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: NOAEL: 500 mg/kg body weight Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Symptoms: No adverse effects Remarks: No significant adverse effects were reported |
|-------------------------------|---|---|

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: NOAEL: 20.9 mg/kg body weight
Embryo-foetal toxicity: 8.3 mg/kg body weight
Result: foetal abnormalities

| | | |
|------------------------------------|---|--|
| Reproductive toxicity - Assessment | : | Clear evidence of adverse effects on development, based on animal experiments. |
|------------------------------------|---|--|

Cellulose:

| | | |
|----------------------|---|---|
| Effects on fertility | : | Test Type: One-generation reproduction toxicity study Species: Rat |
|----------------------|---|---|

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Application Route: Ingestion

Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Milbemycin Oxime:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Dog
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

Test Type: Embryo-foetal development
Species: Dog
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information.

Components:

Lufenuron (ISO):

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT - repeated exposure

Causes damage to organs (Central nervous system, Lungs, Liver, Stomach) through prolonged or repeated exposure if swallowed.

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

Lufenuron (ISO):

Exposure routes : Oral
Target Organs : Central nervous system, Lungs, Liver, Stomach
Assessment : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Milbemycin Oxime:

| | |
|-----------------|--|
| Exposure routes | : Ingestion |
| Target Organs | : Central nervous system |
| Assessment | : Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less. |

Repeated dose toxicity

Components:

Lufenuron (ISO):

| | |
|-------------------|--|
| Species | : Rat |
| NOAEL | : 5.34 mg/kg |
| Application Route | : oral (feed) |
| Exposure time | : 4 Months |
| Target Organs | : Central nervous system, digestive system |
| Symptoms | : central nervous system effects |

| | |
|-------------------|---|
| Species | : Rat |
| NOAEL | : 1.93 mg/kg |
| Application Route | : oral (feed) |
| Exposure time | : 2 yr |
| Symptoms | : central nervous system effects, Convulsions |

| | |
|-------------------|---|
| Species | : Mouse |
| NOAEL | : 2.12 mg/kg |
| Application Route | : oral (feed) |
| Exposure time | : 18 Months |
| Target Organs | : Central nervous system, Liver, Prostate |
| Symptoms | : central nervous system effects, Convulsions |

| | |
|-------------------|---|
| Species | : Dog |
| NOAEL | : 7.02 mg/kg |
| Application Route | : oral (feed) |
| Exposure time | : 1 yr |
| Target Organs | : Central nervous system, Liver, Lungs |
| Symptoms | : Convulsions, Fatality, Irregularities |

Cellulose:

| | |
|-------------------|----------------------|
| Species | : Rat |
| NOAEL | : $\geq 9,000$ mg/kg |
| Application Route | : Ingestion |
| Exposure time | : 90 Days |

Starch:

| | |
|-------------------|---------------------------|
| Species | : Rat |
| NOAEL | : $\geq 2,000$ mg/kg |
| Application Route | : Skin contact |
| Exposure time | : 28 Days |
| Method | : OECD Test Guideline 410 |

Milbemycin Oxime:

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

| | | |
|-------------------|---|----------------------------------|
| Species | : | Rat |
| NOAEL | : | 3 mg/kg |
| LOAEL | : | 15 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |
| Symptoms | : | Liver disorders, Blood disorders |

| | | |
|-------------------|---|-----------|
| Species | : | Dog |
| LOAEL | : | 8.6 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 3 Days |
| Symptoms | : | Tremors |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Lufenuron (ISO):

| | | |
|---------------------|---|--|
| General Information | : | Remarks: May be harmful if swallowed. May cause neurotoxic effects. |
|---------------------|---|--|

Milbemycin Oxime:

| | | |
|-----------|---|---|
| Ingestion | : | Symptoms: Salivation, Convulsions, Diarrhoea, Weakness, Vomiting, Tremors, Coma Remarks: Based on Animal Evidence |
|-----------|---|---|

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Lufenuron (ISO):

| | | |
|------------------|---|---|
| Toxicity to fish | : | LC50 (Oncorhynchus mykiss (rainbow trout)): > 73,100 µg/l Exposure time: 96 h Method: OECD Test Guideline 203 |
|------------------|---|---|

LC50 (Oncorhynchus mykiss (rainbow trout)): > 29,000 µg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 370 µg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

| | | |
|---|---|---|
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Americamysis): 0.042 µg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 |
|---|---|---|

EC50 (Daphnia magna (Water flea)): 0.41 µg/l
Exposure time: 48 h

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Raphidocelis subcapitata (freshwater green alga)): 209 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Scenedesmus subspicatus): 17 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10,000

Toxicity to fish (Chronic toxicity) : NOEC: 80 µg/l
Exposure time: 33 d
Species: Oncorhynchus mykiss (rainbow trout)
Method: OECD Test Guideline 210

NOEC: 20 µg/l
Exposure time: 359 d
Species: Oncorhynchus mykiss (rainbow trout)
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 8.38 µg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

NOEC: 90 µg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

NOEC: 2 µg/l
Exposure time: 21 d
Species: Chironomus riparius (harlequin fly)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 10

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Milbemycin Oxime:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.16 µg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.03 µg/l
Exposure time: 48 h

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Toxicity to algae/aquatic plants : EC50: > 87 µg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 10,000

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.01 µg/l
Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic toxicity) : 10,000

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

Components:

Lufenuron (ISO):

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 28
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 5.12

Milbemycin Oxime:

Bioaccumulation : Bioconcentration factor (BCF): 440

Partition coefficient: n-octanol/water : log Pow: 7

Mobility in soil

Components:

Lufenuron (ISO):

Distribution among environmental compartments : log Koc: 5.38
Method: OECD Test Guideline 106

Other adverse effects

No data available

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

13. DISPOSAL CONSIDERATIONS

Disposal methods

| | | |
|------------------------|---|---|
| Waste from residues | : | Do not dispose of waste into sewer. Dispose of in accordance with local regulations. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

| | | |
|---------------------------|---|---|
| UN number | : | UN 3077 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Milbemycin Oxime, Lufenuron (ISO)) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| Environmentally hazardous | : | yes |

IATA-DGR

| | | |
|--|---|---|
| UN/ID No. | : | UN 3077 |
| Proper shipping name | : | Environmentally hazardous substance, solid, n.o.s. (Milbemycin Oxime, Lufenuron (ISO)) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | Miscellaneous |
| Packing instruction (cargo aircraft) | : | 956 |
| Packing instruction (passenger aircraft) | : | 956 |
| Environmentally hazardous | : | yes |

IMDG-Code

| | | |
|----------------------|---|---|
| UN number | : | UN 3077 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Milbemycin Oxime, Lufenuron (ISO)) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| EmS Code | : | F-A, S-F |
| Marine pollutant | : | yes |

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

16. OTHER INFORMATION

Revision Date : 09.05.2025

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No

SAFETY DATA SHEET

according to the Globally Harmonized System



Milbemycin Oxime / Lufenuron Formulation

| | | | |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 14.04.2025 |
| 4.1 | 09.05.2025 | 6365220-00011 | Date of first issue: 21.09.2020 |

1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN